key: cord-0961069-cpqtmqdq
authors: Hasan, Md. Kamrul; Kamruzzaman, Mohammad; Bin Manjur, Omar Hamza; Mahmud, Araf; Hussain, Nazmul; Alam Mondal, Muhammad Shafiul; Hosen, Md. Ismail; Bello, Martiniano; Rahman, Atiqur
title: Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation
date: 2021-03-05
journal: Heliyon
DOI: 10.1016/j.heliyon.2021.e06435
sha: 7fbd292272b8fb1f7db3ad83b9d82f743dd27658
doc_id: 961069
cord_uid: cpqtmqdq

The Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became a pandemic, resulting in an exponentially increased mortality globally and scientists all over the world are struggling to find suitable solutions to combat it. Multiple repurposed drugs have already been in several clinical trials or recently completed. However, none of them shows any promising effect in combating COVID-19. Therefore, developing an effective drug is an unmet global need. RdRp (RNA dependent RNA polymerase) plays a pivotal role in viral replication. Therefore, it is considered as a prime target of drugs that may treat COVID-19. In this study, we have screened a library of compounds, containing approved RdRp inhibitor drugs that were or in use to treat other viruses (favipiravir, sofosbuvir, ribavirin, lopinavir, tenofovir, ritonavir, galidesivir and remdesivir) and their structural analogues, in order to identify potential inhibitors of SARS-CoV-2 RdRp. Extensive screening, molecular docking and molecular dynamics show that five structural analogues have notable inhibitory effects against RdRp of SARS-CoV-2. Importantly, comparative protein-antagonists interaction revealed that these compounds fit well in the pocket of RdRp. ADMET analysis of these compounds suggests their potency as drug candidates. Our identified compounds may serve as potential therapeutics for COVID-19.

Over the last ten months, scientists have come up with different ways to alleviate the severity of the 91 disease and reduce its contagiousness (Van Kampen et al., 2020) . So far, we have only been able to battle 92 the disease by maintaining social distancing, quarantine and hygiene. Very recently, many countries in the 93 world have already started running the vaccination program (D. D. Li & Li, 2021; Rubin & Longo, 2020) . 94

Yet, due to production and budget limitation it will take considerable time to vaccinate the entire 95 population of the world. Importantly, this is uncertain whether the currently developed vaccines will give 96 durable immunity against the virus. In addition, acquiring newer mutations by the virus may render the 97 vaccines ineffective or the virus may make its way to infect vaccinated individuals. Therefore, discovery 98 of effective drugs for treating COVID-19 patients is an urgent need. The enzyme, RdRp plays a pivotal 99 role in viral replication, having no host homologues and, therefore, developing therapeutics that inhibit 100 the enzyme would not only inhibit viral replication but also minimize any potential risks in host cells. Ünal, 2020; Sinha & Balayla, 2020). Although remdesivir, an experimental Ebola virus drug, has been 105 approved for emergency use only for hospitalized patients and recent clinical data suggest a moderate 106 clinical improvement by reducing the recovery period (Beigel et al., 2020) , however, no impact on 107 mortality; therefore, the potentiality of the drug is not as promising as expected. Thus, identifying novel 108 therapeutics that have the potential to effectively combat the disease is an unmet need. To address this, 109

we, herein, virtually screened FDA approved RdRp inhibitor drugs and their structural analogues (~2400 110 compounds) based on molecular docking analysis of these compounds in order to identify drug candidates 111 that can potentially inhibit SARS-CoV-2 RdRp. SARS-CoV nsp7 and nsp8 activate and confer the 112 processivity to the nsp12 RNA-synthesizing activity (Subissi et al., 2014) . SARS-CoV-2 RNA-dependent 113 RNA polymerase (PDB ID: 6M71) is a complex with those cofactors (nsp7 and nsp8) and nsp12 is a 114 target for nucleotide analog of several antiviral inhibitors and the structure may provide a basis for new 115 antiviral therapeutics (Gao et al., 2020 

The crystal structure of RdRp of SARS-CoV-2 was collected from the RCSB Protein Data Bank 

As mentioned above the structural analogues of the inhibitor drugs were obtained from the ZINC database 143 (Sterling & Irwin, 2015) for the best optimal hit against the mentioned target (Figure 1 

The protein-ligand binding interaction of chosen protein-ligand complexes was performed using Complexes were solvated with TIP3P water model employing a dodecahedron box with a 12 Å packing 176 using tleap available in Amber16 package (Case et al., 2005) . The systems were then neutralized with Na + 177 and Clions until neutrality. The protein, water molecules, and ions were defined by the ff14SB AMBER 178 force field (Duan et al., 2003) . Ligands were parameterized by assigning AM1-BCC atomic charges 179 employing the general AMBER force field (GAFF) (Wang et al., 2004) . Simulations were run at the NPT 180 ensemble at 310 K via a Langevin thermostat, 1 bar of pressure, and an isotropic Berendsen barostat. 181

Periodic boundary conditions (PBC) were considered with a cutoff of 10 Å for the nonbonded 182 interactions, whereas the electrostatic term was described via the PME method (Darden et al., 1993) . A approved drugs and their best hit analogues suggest high affinity binding ( Table 1 and Table 2 ), further 214 strengthening our initial findings. It is important to mention that the structural analogues were predicted to 215 have better binding than the existing FDA-approved drugs tested in this study, as evident from the 216 binding scores (Table 1 and Table 2) . Discngine,") and show that all the 8 ligands bind efficiently and interact well with RdRp (Figure 2) . 223

The RMSD analysis plots show the mobility of the receptor-ligand complexes and constant values 225 suggest that the system reached equilibrium (Figure 3) . The RMSD values of backbone atoms reached an 226 equilibrium state between 20 to 30 ns with RMSD values that oscillated between 2.7 to 3.2 Å. Based on 227 this, further analyses were performed considering the last 30 ns. 228

Analysis of the receptor-ligand complexes showed that 3 (ZINC000012863240, ZINC000049581065, and 230 ZINC000072460420) out of 8 ligands lost interactions with the receptor at the beginning of the 231 simulations, therefore, these three compounds were not considered in further analyses. Based on the 232 simulation time in which systems reached equilibrium, a cluster analysis was performed using a cut-off of 233 2.5 Å to observe the main residues involving in stabilizing the ligand inside the binding site (Figure 2) . 234

The ligand orientation at the binding site is shown in 

To further assess the thermodynamic feasibility of binding of the top-5 ligands to RdRp, MMGBSA 251 method was used to calculate the binding free energy of the protein-ligand complex. Simulation runs were 252 extracted to calculate the MMGBSA free binding energy. All of the five compounds showed negative 253 binding free energy; suggesting successful binding throughout the simulation ( Table 3) . The molecular 254 mechanic energy showed that Van der Waals energy (ΔEvdw + ΔGnpol, sol) was the main force for 255 stabilizing the ligand at the binding site ( 

Drug bioavailability, metabolism and toxicity are important factors that may limit the efficacy of a drug in 264 clinical settings. Therefore, to determine whether the potential drug candidates are effectively 265 bioavailable and have potentially no carcinogenicity to organs in human, the top-5 ligands were assessed 266 based on their ADMET profile ( Table 4 ) and all of the 5 drug candidates were found to have no potential 267 toxicity (residing below toxicity classes of 4 and 5), supporting their safety for human use. 19, we adopted a computational approach to identify potential drug candidates. In this study, the 297 inhibitory potential of the candidate drugs targeting SARS-CoV-2 RdRp was predicted via screening from 298 a library of compounds containing existing, approved drugs against RNA viruses and their structural 299 analogues. Careful evaluation of the library by employing various computational screening methods 300 yielded 5 candidate drugs and gave an insight into the potential of these prospective drugs against SARS-301

The computational screening approach enables the rapid discovery of promising compounds for 303 developing effective therapeutics against SARS-CoV-2. It has been shown that less binding energy 304 denotes more affinity of a compound for binding to its target (Ortiz et al., 1995) . To elucidate the binding 305 affinity to RdRp, the library of compounds was docked against RdRp using the PyRx tool (Dallakyan & 306 Olson, 2015) . Since among the approved RdRp drugs the binding site of only remdesivir to SARS-CoV-2 307

RdRp has already been elucidated as well as the in vitro studies of remdesivir showed some promises we, 308 for our screening, selected 11 critical amino acids in RdRp pocket where the drug interacts. Of note, 309 compounds with a binding affinity of -7.5 Kcal/mol or less are evaluated as potent inhibitors of enzymatic 310 mechanisms (R Yunta, 2016). Based on binding affinities, top ranked 8 compounds were selected for 311 further analysis. None of the approved drugs, including remdesivir, showed significant binding, perhaps 312 these best hits are better candidates than the mother compounds. (Table 3) . 340

ZINC000014751834 are structural analogues of tenofovir, lopinavir and ritonavir, respectively and this 342 study predicted them to be more potent inhibitors of SARS-CoV-2 RdRp compared to their mother drugs. 343

Physicochemical properties of the selected compounds were studied using ADMET (Hodgson, 2001) to 344 determine their drug-likeness properties. ADMET evaluates the molecular properties of a drug that are 345 J o u r n a l P r e -p r o o f crucial for pharmacokinetics of the drug in human body, which includes absorption, distribution, 346 metabolism, and excretion (ADME). Selected drugs showed satisfactory ADMET profile, which may 347 explain by the fact that these are analogues of available drugs for which safety and efficacy have already 348 been proven. Although 4 of the 5 compounds show hepatotoxicity as predicted from ADMET, however, 349 the level of toxicity to the liver, if any, needs to be addressed in preclinical and clinical settings in future. 350

Our work is limited by the fact that the potential drugs were identified solely by computational approach. 351

Wet lab validation is required which is beyond the scope of our current work, however, is an area that we 352 will try to address in the future. 353

The present in silico investigation explored the potentiality of the analogues of the available drugs in 355

inhibiting SARS-CoV-2 RdRp. The result of the virtual screening yielded top-5 hit ligands. An ideal 356 drug is presumed to not only have a high affinity to a specific target but also should have the drug 357 likeness properties. Taking into account, for better prediction the binding affinities predicted by 358 MMGBSA, binding modes and further 50 ns MD simulation were also determined, and five ligands 359 (ZINC000005605139, ZINC000006094731 ZINC000012161475, ZINC000014751834, and 360 ZINC000014882040) were found to be the most favorable ones. Considering the safety issue of these 361 drugs, all five compounds showed a good ADMET profile. The identified 5 drug candidates may have 362 therapeutic potential in COVID-19, however, our study offers further preclinical and clinical investigation 363 to prove their safety and efficacy against SARS-CoV-2. 364 Table 2 . Autodock Vina docking results of the top-ranking ligands Table 3 . Binding free energy components of protein-ligand systems (in units of kcal/mol). 

PHENIX: A 371 comprehensive Python-based system for macromolecular structure solution

Investigating the 376 binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs 377 targeting RdRp and Mpro of SARS-CoV-2

Potential use of 380 RNA-dependent RNA polymerase (RdRp) inhibitor against COVID-19 infection

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Binding mechanism of kinase inhibitors to EGFR and T790M

L858R/T790M mutants through structural and energetic analysis

Mechanisms of coronavirus cell 391 entry mediated by the viral spike protein

Current Landscape of Antiviral Drug Discovery

From Corona Virus to Corona Crisis: The Value of An Analytical and 397

Knowledge-based repositioning of the anti-HCV direct 400 antiviral agent Sofosbuvir as SARS-CoV-2 treatment

The Amber biomolecular simulation programs

Why re-purposing HIV drugs Lopinavir/ritonavir to inhibit the SARS-406

Cov2 protease probably wont work -but re-purposing Ribavirin might since it has a very similar 407 binding site within the RNA-polymerase

Coronavirus Update (Live): 109,706,925 Cases and 2,419,664 Deaths from COVID-19 Virus Pandemic -409

Small-molecule library screening by docking with PyRx

Particle mesh Ewald: An N·log(N) method for Ewald sums 413 in large systems

The PyMOL Molecular Graphics System

A Point-Charge Force Field for Molecular 419 Mechanics Simulations of Proteins Based on Condensed-Phase Quantum Mechanical Calculations

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 422 RNA dependent RNA polymerase (RdRp): A molecular docking study

Andrographolide As a Potential Inhibitor of 425 SARS-CoV-2 Main Protease: An In Silico Approach

Comparison of the COVID-2019 (SARS-CoV-2) 428 pathogenesis with SARS-CoV and MERS-CoV infections

Performance 431 Comparison of Generalized Born and Poisson Methods in the Calculation of Electrostatic Solvation 432 Energies for Protein Structures

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Treating HCV with ribavirin analogues and ribavirin-like molecules

SWISS-MODEL and the Swiss-PdbViewer: An environment for 441 comparative protein modeling

Coronavirus puts drug repurposing on the fast track

Delayed Initiation of 446 Remdesivir in a COVID-19-Positive Patient

ADMET -Turning chemicals into drugs. Rapidly resolving the pharmacokinetic and 449 toxicological properties of drug candidates remains a key challenge for drug developers

Ribavirin mode of action in chronic 452 hepatitis C: from clinical use back to molecular mechanisms

Clinical features 456 of patients infected with 2019 novel coronavirus in Wuhan

Acute Myocardial Infarction after Laboratory-Confirmed Influenza 459 Infection

Combined drug repurposing and virtual screening strategies with molecular 463 dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro). and Dynamics

In silico and in vitro evaluation of kaempferol as a potential inhibitor of the SARS-CoV-2 467 main protease (3CLpro)

Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-470

Polymerase Inhibition from SARs-CoV-2 with Natural Products. Interdisciplinary Sciences: 471 Computational Life Sciences

SARS-CoV-2: vaccines in the pandemic era

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Kidney Dysfunctions of COVID-19 Patients

Synthesis and inhibitory effects 482 of novel pyrimido-pyrrolo-quinoxalinedione analogues targeting nucleoproteins of influenza A virus 483 H1N1

Coronaviruses and SARS-CoV-2: A Brief Overview

The potential 488 chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase

Use of antiviral drugs to reduce COVID-19 transmission. The Lancet 491 Global Health

Seasonal influenza 493 infections and cardiovascular disease mortality

Prediction of Drug Binding Affinities by

pkCSM: Predicting small-molecule 499 pharmacokinetic and toxicity properties using graph-based signatures

Docking and Ligand Binding Affinity: Uses and Pitfalls

SARS-CoV-2 Vaccination -An Ounce (Actually, Much Less) of 504 Prevention

Bridging molecular docking to molecular dynamics in exploring ligand-507 protein recognition process: An overview

Remdesivir and SARS-CoV-2: Structural requirements at both 511 nsp12 RdRp and nsp14 Exonuclease active-sites

Estimation of ADME properties with substructure 514 pattern recognition

Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, 517 diagnosis, treatment and vaccine planning

Antiviral treatment of covid-19

Hydroxychloroquine and covid-19

ZINC 15 -Ligand Discovery for Everyone

One severe acute respiratory syndrome coronavirus 527 protein complex integrates processive RNA polymerase and exonuclease activities

Characterization of 531 the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of 532 RBD protein as a viral attachment inhibitor and vaccine. Cellular and Molecular Immunology

AutoDock Vina: Improving the speed and accuracy of docking with a 535 new scoring function, efficient optimization, and multithreading

Algorithms for macromolecular dynamics and 538 constraintdynamics

Shedding of 544 infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and 545 key determinants

Medicinal Chemistry and the Molecular Operating Environment 547 (MOE): Application of QSAR and Molecular Docking to Drug Discovery. Current Topics in 548 Medicinal Chemistry

Development and testing 550 of a general Amber force field

Coronavirus genomics and bioinformatics 553 analysis. Viruses

AdmetSAR 2.0: 555 Web-service for prediction and optimization of chemical ADMET properties

Binding Mechanism of Remdesivir to SARS-CoV-2 RNA Dependent 558 RNA Polymerase

SwissSimilarity: A Web Tool for Low to Ultra 560

High Throughput Ligand-Based Virtual Screening

ZINC000006 094731 (7R,8R,9S,10S

(oxolan-2-ylmethyl)-5-propylimidazolidine-2,4-dione -8.9 ZINC000014 751834 [3-(4-Hydroxypiperidine-1-carbonyl)-1-(2-phenylethyl)-6,7-dihydro-4H-pyrazolo

4-Dihydro-2H-1,5-benzodioxepin-7-yl)-2-(hydroxymethyl)-5-methyl

The authors acknowledge Saeed Anwar (University of Alberta) and Sohel Mahmud (Tejgaon College, 366National University of Bangladesh) for helping with the writing of the manuscript. 367